Harry P. Erba, MD, PhD of the University of Alabama at Birmingham School of Medicine, presents a press brief on A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) at the 58th ASH Annual Meeting in San Diego, CA.
Phase 1b Study of Patients with Newly Diagnosed AML
